Skip to main content
. 2023 May 18;15(5):1524. doi: 10.3390/pharmaceutics15051524

Figure 2.

Figure 2

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) chromatograms of (A) a blank human plasma sample, (B) rucaparib, niraparib, and olaparib spiked in human plasma at the lowest concentration levels (100 ng/mL, 60 ng/mL, and 140 ng/mL, respectively), (C) a blank DBS sample, and (D) rucaparib, niraparib, and olaparib in the DBS sample at the lowest concentration levels.